Biocom Welcomes Two New Board Members

Biocom has added two new members to its board, appointing Aaron K. Cohen and Bradley Wolff to the governing body.

“Mr. Cohen and Mr. Wolff are valuable additions to our board of directors, which consists of prominent life science leaders with deep industry knowledge representing regions across the state,” Biocom President/CEO Tim Scott said. “As the life science industry evolves, we rely on the expertise and insight from our board to ensure we continue to equip member companies with vital resources as well as advance key initiatives that foster growth and innovation.”

Cohen leads federal and state government affairs and public policy teams as the head of Neurocrine Biosciences’ Washington, D.C., office. He has more than 25 years of experience in public policy and political strategy on Capitol Hill and in the private sector.

Cohen’s career has thus far encompassed working for U.S. Senate members, authoring and facilitating the passage of multiple pieces of legislation through Congress (that were signed into law) on healthcare issues related to Medicare beneficiaries, providers, women’s health, and animal health. In the private sector, he has either led or assisted in securing legislative and regulatory victories for clients on issues such as healthcare, tax policy, and veterans’ affairs. Cohen earned a bachelor’s degree in political science from Pepperdine University.

Wolff is a senior managing director in Evercore’s strategic advisory practice. He has more than 25 years of investment banking experience advising companies in the healthcare industry and is based in Menlo Park, Calif. Wolff has advised on many of the most prominent and complex transactions across the pharmaceutical and biotechnology industries, covering the full spectrum of M&A advisory and financings, including equities and debt instruments.

Wolff’s particular expertise is in devising customized solutions to the more challenging issues facing clients, whether in capital markets or in a strategic advisory context such as M&A structured partnerships, separation transactions, and royalty transactions. Wolff earned a bachelor of science degree from the University of Minnesota’s Carlson School of Management and an MBA from the Anderson School at UCLA.

Biocom is the largest life science membership association, representing companies across California and major life science markets worldwide. Founded in 1995, Biocom aims to drive innovation and industry competitiveness across the life science ecosystem. Its community includes biotechnology, pharmaceutical, medical device, genomics, and diagnostics companies at every stage, as well as research institutions, investors, service providers, and emerging technology innovators.

Biocom works on behalf of its members to build meaningful connections and deliver valuable insights through conferences and events, expand access to funding and partnering opportunities, provide group purchasing solutions that drive efficiency and savings, champion policy and advocacy that protects and advances innovation, and strengthen talent pipelines through workforce development. Biocom maintains offices in San Diego, Los Angeles, and the San Francisco Bay Area, with satellite offices in Sacramento; Washington, D.C.; and Tokyo, and a growing presence in Seattle, bridging regional ecosystems and global markets to strengthen growth.